S. boulardii reduces CDI riskSaccharomyces boulardii prophylaxis for targeted antibiotics and infectious indications to reduce healthcare facility-onset Clostridioides difficile infection.
Highly relevant for clinical practice
We examined whether Saccharomyces boulardii can help lower the risk of Clostridioides difficile infection (HO-CDI) in patients receiving antibiotics, particularly for pneumonia. Using a retrospective matched-cohort study, we compared patients on high-risk antibiotics who received S. boulardii to those who didn’t.
Our findings showed a significant 57% reduction in HO-CDI risk for pneumonia patients on S. boulardii, and a remarkable 76% reduction for those on ceftriaxone. This suggests that S. boulardii could be a valuable prophylaxis option in specific hospital settings.
Read More
Probiotics reduce VAP incidenceA four-probiotic preparation for ventilator-associated pneumonia in multi-trauma patients: results of a randomized clinical trial.
High relevance for clinical practice
We assessed whether a specific probiotic regimen could help prevent ventilator-associated pneumonia (VAP) in multi-trauma patients who required long-term mechanical ventilation. In a randomized, controlled trial, patients received either a probiotic preparation—including Saccharomyces boulardii—or a placebo.
The results showed that probiotics significantly lowered VAP incidence from 28.3% to 11.9% and reduced sepsis rates alongside hospital stays. This suggests that probiotics, particularly when administered both enterally and topically, can effectively enhance recovery for critically ill patients.
Read More
Saccharomyces boulardii improves pneumonia treatment[Clinical effect of Saccharomyces boulardii powder combined with azithromycin sequential therapy in treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia].
Significant for pediatric treatment
We investigated how Saccharomyces boulardii, when paired with azithromycin, affects children suffering from diarrhea due to Mycoplasma pneumoniae pneumonia.
In our study, 88 children were split into two groups; one received standard treatment, while the other got Saccharomyces boulardii powder alongside their treatment. We compared both groups on various aspects including recovery time, hospital stay, and frequency of bowel movements.
The results showed that the combination therapy led to improved symptoms, shorter hospital stays, less frequent bowel issues, and better overall outcomes, without increasing the risk of side effects.
Read More
We looked into the effectiveness of a new four-probiotic formula during and after colorectal cancer surgery. In a double-blind, placebo-controlled study, patients were given either probiotics or a placebo before and after their procedures.
We found that those taking the probiotics had significantly fewer complications, including pneumonia and surgical site infections. Specifically, pneumonia rates dropped from 11.3% in the placebo group to just 2.4% in those receiving probiotics. This promising formulation may hold potential for improving recovery after surgery.
Read More